NCT03140657View on ClinicalTrials.gov

The Effects of Nanocurcumin on Treg Cells and Th17 Cells Responses in Ankylosing Spondylitis Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 29, 2017

Primary Completion Date

November 7, 2017

Study Completion Date

January 18, 2018

Conditions
Ankylosing Spondylitis
Interventions
DRUG

Nanocurcumin

Nanocurcumin capsules (the formulation of curcumin nanoparticles, Exirnanosina). Subjects randomized to Nanocurcumin Arm will receive 80 mg/day for 4 months

DRUG

Placebo

Subjects randomized to Placebo Arm will receive placebo in the form of capsules for 4 months

Trial Locations (1)

0413

Connective Tissue Diseases Research Center, Tabriz

All Listed Sponsors
lead

Tabriz University of Medical Sciences

OTHER

NCT03140657 - The Effects of Nanocurcumin on Treg Cells and Th17 Cells Responses in Ankylosing Spondylitis Patients | Biotech Hunter | Biotech Hunter